Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models

McCampbell, Alex, Cole, Tracy, Wegener, Amy J., Tomassy, Giulio S., Setnicka, Amy, Farley, Brandon J., Schoch, Kathleen M., Hoye, Mariah L., Shabsovich, Mark, Sun, Linhong, Luo, Yi, Zhang, Mingdi, Thankamony, Sai, Salzman, David W., Cudkowicz, Merit, Graham, Danielle L., Bennett, C. Frank, Kordasiewicz, Holly B., Swayze, Eric E., Miller, Timothy M.·2018·Journal of Clinical Investigation
DOI 10.1172/jci99081

Cited by (279)

Items 201–279 of 279

  1. Neurofilaments in neurologic disease
    Christina Mousele, David Holden, Sharmilee Gnanapavan · 2024 · Advances in clinical chemistry
  2. Targets and Gene Therapy of ALS (Part 1)
    O. A. Shiryaeva, Christina Tolochko, Tatiana M. Alekseeva, Vyacheslav A. Dyachuk · 2025 · International Journal of Molecular Sciences
  3. The prion-like effect and prion-like protein targeting strategy in amyotrophic lateral sclerosis
    Yang Wenzhi, Liu Xiangyi, Fan Dongsheng · 2024 · Heliyon
  4. Oligonucleotide therapeutics for neurodegenerative diseases
    Victor C. Li, Yunlong Huang · 2024 · NeuroImmune Pharmacology and Therapeutics
  5. Theme 7 Pre-clinical therapeutic strategies
    Vittoria Lombardi, Daniele Carassiti, Gavin Giovannoni, Ching‐Hua Lu, Rocco Adiutori, Andrea Malaspina · 2019 · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
  6. A case of SOD1 deficiency: implications for clinical trials
    Lucy E Farrimond, Kevin Talbot · 2022 · Brain
  7. Enhancing the delivery of SOD1 antisense oligonucleotides to the murine brain using lipid nanoparticles and image-guided focused ultrasound
    Gayathri R. Ediriweera, Nicholas L. Fletcher, Gary Cowin, Joshua D. Simpson, Liyu Chen, Joanna Marta Wasielewska, Jeremy Stephen Lum, Luke McAlary, Mikayla L. Brown, Justin J. Yerbury et al. · 2022 · Research Square
  8. Non-cell autonomous autophagy in amyotrophic lateral sclerosis: A new promising target?
    Francesca Rosso, Rocio Magdalena, Carola Torazza, Francesca Bacchetti, Marco Milanese, Angelo Poletti, Giambattista Bonanno, Riccardo Cristofani, Tiziana Bonifacino · 2025 · Neurobiology of Disease
  9. MOLECULAR DOCKING STUDIES OF MONOMERIC WILDTYPE AND MUTANT (H81A, H49R) SOD1 WITH EDARAVONE AND RILUZOLE
    RADHIKA NAGRE, VAEESHNAVI BUWA · 2022 · International Journal of Chemistry Research
  10. Tofersen: Silver Lining or Hyperbole??
    Tanushree Chawla, Vinay Goyal · 2023 · Annals of Indian Academy of Neurology
  11. Applications and Developments of Gene Therapy Drug Delivery Systems for Neurological Disorders
    Ngoc Hong Nguyen, Phuong‐Trang Nguyen‐Thi, Thuy Trang Nguyen, Vu Khac Hoang Bui, Nhat Thang Thi Nguyen, Vo Van Giau · 2024 · Advanced Therapeutics
  12. A NOTCH3 pathogenic variant influences osteogenesis and can be targeted by antisense oligonucleotides in induced pluripotent stem cells
    ERNESTO M. CANALIS, Jungeun Yu, Lauren Schilling, Paymaan Jafar‐Nejad, Michele Carrer · 2025 · PLoS ONE
  13. SNP Analysis of the SOD1 gene involved in Amyotrophic Lateral Sclerosis (ALS)
    Hetal Patel, Anandita Banerjee, Pritha Saha, Subramaniyan Divya, Palaniyandi Ravanan, Priti Talwar · 2025 · Journal of Taibah University for Science
  14. Tofersen - A Ray of Hope for ALS Patients : A Mini Review
    Hara Prasad Mishra · 2023 · Journal of Pharmacovigilance and Drug Research
  15. Local administration of a novel siRNA modality into the CNS extends survival and improves motor function in the SOD1 G93A mouse model for ALS
    Chunling Duan, Moorim Kang, Xiaojie Pan, Zubao Gan, Vera Huang, Guanlin Li, Robert F. Place, Long‐Cheng Li · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  16. Enclosure of siRNA in Alternately Hydrophilic–Hydrophobic Double-Layered Nanoarchitectures for Promoted RNAi
    Jinxuan He, Zhixiang Mou, Yuchen Tian, Liangping Yu, Tianjun Guan, Qixian Chen, Lan Chen · 2022 · ACS Applied Polymer Materials
  17. Cell and gene therapy for amyotrophic lateral sclerosis
    Alvar Paris, András Lakatos · 2024 · Handbook of clinical neurology
  18. miR-146a is a pleiotropic regulator of motor neuron degeneration
    Dylan A. Galloway, Hunter L. Patterson, Mariah L. Hoye, Tao Shen, Mark Shabsovich, Kathleen M. Schoch, Cindy V. Ly, Jonathan S. Mill · 2026 · Proceedings of the National Academy of Sciences
  19. Therapeutic suppression of Tubb4a rescues H-ABC leukodystrophy
    Sunetra Sase, Julia Liao Hacker, Prabhat R. Napit, Anjali Bhagavatula, Sarah Woidill, Annemarie D’Alessandro, Marisa A. Jeffries, Akshata Almad, Asako Takanohashi, Quasar Saleem Padiath et al. · 2026 · Molecular Therapy
  20. Tofersen in SOD1-associated amyotrophic lateral sclerosis: From molecular mechanisms to regulatory milestones
    Antonio J. Braza, Montserrat Viñas-Bastart, Maria Sureda-Rosich, Beliu García-Parra, Josep M. Guiu-Segura, Pilar Modamio · 2026 · European Journal of Pharmaceutical Sciences
  21. Estimation of human brain fluid clearance using intrathecal imaging contrast agents
    Per Kristian Eide, Aslan Lashkarivand, Susanne Sørensen Hernes, Geir André Ringstad, Markus Herberg Hovd · 2026 · Fluids and Barriers of the CNS
  22. Intravenous administration of an engineered AAV9-gene-silencing vector suppresses human SOD1 and extends survival in an ALS mouse model
    Fang Wan, Jinchen He, Hong Ma, Debora Pires-Ferreira, Veena Kumanan, Ji Sun Lee, Xiupeng Chen, Ran He, Qin Su, T. F. Gallagher et al. · 2026 · Nature Communications
  23. To scramble or not: Steric blocking 2′-MOE/PS control antisense oligonucleotides across cellular models
    Edith De Bruycker, Manon Bouckaert, Kyana Van Acker, Emma Delanote, Leander Meuris, Álvaro González-Cid, Hanne Lenaerts, Lode Denolf, Katrien Remaut, An Staes et al. · 2026 · Molecular Therapy — Nucleic Acids
  24. Neurotoxicity and ALS: Insights into Pathogenesis
    Steve Vucic, Matthew C. Kiernan · 2021 · Springer eBooks
  25. Antisense oligonucleotide drugs for neurological and neuromuscular disease
    Roger M. Lane, C. Frank Bennett · 2020 · Elsevier eBooks
  26. Molecular and Genetic Therapies
    Pushpa Narayanaswami, Saša Živković · 2021 · Elsevier eBooks
  27. Amyotrophic Lateral Sclerosis: Neurochemical Biomarkers
    Federico Verde, Nicola Ticozzi · 2022 · Springer eBooks
  28. Antisense Oligonucleotides: Concepts and Pharmaceutical Applications
    A Kenneth Araya, David Arias, Karla Coto, María Rebeca López, Joselyn Rivera, Juan José Mora · 2023 · Borneo Journal of Pharmacy
  29. Antisense oligonucleotides targeting a NOTCH3 mutation in male mice ameliorate the cortical osteopenia of lateral meningocele syndrome
    ERNESTO M. CANALIS, Magda Mocarska, Lauren Schilling, Paymaan Jafar‐Nejad, Michele Carrer · 2023 · Bone
  30. Superoxide Dismutase and Catalase
    Daret K. St. Clair, Edward J. Kasarskis, William H. St. Clair, Luksana Chaiswing · 2024 · Elsevier eBooks
  31. Cure the Incurable: Update of Treatment in Inherited Neuromuscular Disorders
    Cheng-Hao Yu, Kuan‐Lin Lai · 2024 · Acta Neurologica Taiwanica
  32. Maximizing the translational potential of neurophysiology in amyotrophic lateral sclerosis: a study on compound muscle action potentials
    Scott McKinnon, Zekai Qiang, Amy F. A. Keerie, Tyler R. Wells, Pamela J. Shaw, James J. P. Alix, Richard J. Mead · 2025 · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
  33. Neural Excitatory/Inhibitory Imbalance in Motor Aging: From Genetic Mechanisms to Therapeutic Challenges
    Xuhui Chen, Ya Wang, Yongning Zhang, Xucheng Li, Le Zhang, Shangbang Gao, Cuntai Zhang · 2025 · Biology
  34. RNA Metabolism and Therapeutics in Amyotrophic Lateral Sclerosis
    Orietta Pansarasa, Stella Gagliardi, Daisy Sproviero, Cristina Cereda · 2020 · IntechOpen eBooks
  35. Neuroprotection in Amyotrophic Lateral Sclerosis
    Kewal K. Jain · 2019 · Springer protocols handbooks/Springer protocols
  36. Neurotoxicity and ALS: Insights into Pathogenesis
    Steve Vucic, Matthew C. Kiernan · 2022 · Springer eBooks
  37. Expression of a miRNA targeting mutated SOD1 in astrocytes induces motoneuron plasticity and improves neuromuscular function in ALS mice
    Cylia Rochat, Nathalie Bernard‐Marissal, Sylvain Pradervand, Florence Evelyne Perrin, Cédric Raoul, Patrick Aebischer, Bernard Laurent Schneider · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  38. A Cultured Sensorimotor Organoid Model Forms Human Neuromuscular Junctions
    João D. Pereira, Daniel M. DuBreuil, Anna‐Claire Devlin, Aaron Held, Yechiam Sapir, Eugene Berezovski, James Hawrot, Katherine Dorfman, Vignesh Chander, Brian J. Wainger · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  39. HuD (ELAVL4) gain-of-function impairs neuromuscular junctions and induces apoptosis in in vitro and in vivo models of amyotrophic lateral sclerosis
    Beatrice Silvestri, Michela Mochi, Darilang Mawrie, Valeria de Turris, Alessio Colantoni, Beatrice Borhy, Margherita Medici, Eric Nathaniel Anderson, Maria Giovanna Garone, Christopher Patrick Zammerilla et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  40. Antisense treatment alleviates ALS in animals
    Ian Fyfe · 2018 · Nature Reviews Neurology
  41. Introduction to Novel Motor Neuron Disease
    Humberto Foyaca Sibat, Lourdes de Fátima Ibañez Valdés · 2020 · IntechOpen eBooks
  42. Development of a molecular therapy for the SOD1 familial variant of ALS
    Richard Alan Smith, Timothy M. Miller, Don W. Cleveland, Frank Bennett · 2020 · Elsevier eBooks
  43. A copper chaperone-mimetic polytherapy for SOD1-associated amyotrophic lateral sclerosis
    Luke McAlary, Victoria K. Shephard, Gareth S. A. Wright, Justin J. Yerbury · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  44. Theme 07 - PRE-CLINICAL THERAPEUTIC STRATEGIES
    2021 · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
  45. Faculty Opinions recommendation of Antisense oligonucleotide therapies for neurodegenerative diseases.
    Matthew David Disney · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  46. Faculty Opinions recommendation of Scn8a Antisense Oligonucleotide Is Protective in Mouse Models of SCN8A Encephalopathy and Dravet Syndrome.
    Laurent Villard · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  47. IV. Gene Therapy for Amyotrophic Lateral Sclerosis
    Makoto Urushitani · 2022 · Nihon Naika Gakkai Zasshi
  48. Therapeutic strategies based on genetic interventions
    Rena C. Baek, Patrick F. Finn, Paolo G.V. Martini · 2024 · Elsevier eBooks
  49. Maximising the translational potential of neurophysiology in amyotrophic lateral sclerosis: a study on compound muscle action potentials
    Scott McKinnon, Zekai Qiang, Amy F. A. Keerie, Tyler R. Wells, Pamela J. Shaw, James J. P. Alix, Richard J. Mead · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  50. Antisense oligonucleotide drugs for neurological and neuromuscular diseases
    Roger M. Lane, C. Frank Bennett · 2024 · Elsevier eBooks
  51. SCAD Delivery Platform: A Novel Approach for Efficient CNS and Extrahepatic Oligonucleotide Therapeutics
    Moorim Kang, Wei-Hsiang Lin, Feifei Xu, Xiaojie Zhou, Chunyan Si, Kunshan Liu, Jian Dai, J. He, Ian Schacht, Yichen Li et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  52. SCAD: A Modular Platform for Efficient Delivery of Duplex RNA to the CNS and Beyond
    Long‐Cheng Li, Moorim Kang, Wei-Hsiang Li, Feifei Xu, Xiaojie Zhou, Chunyan Si, Jian Dai, J. He, Ian Schacht, Yichen Li et al. · 2025 · Research Square
  53. Performing Compound Motor Action Potential Measurement in Zebrafish: A Description of Methodology and a Comparison Between Healthy and ALS ‐Affected Animals
    Seward B. Rutkove, Gaurav Tiwari, Anjali K. Nath · 2025 · Muscle & Nerve
  54. BLOC1S1 depletion via splice-switching oligonucleotides improves mitochondrial respiration and rescues ALS phenotypes
    Jin‐Hui Hor, Jin Rong Ow, Winanto Ng, Boominathan Ramasamy, Tommaso Tabaglio, Kimberly Ngee Hui Lim, Muhammad Ikhsan Bin Muzakar, Valerie Jing Wen Lim, Rajasekhar Reddy Gurrampati, Ravisankar Rajarethinam et al. · 2025 · Molecular Therapy
  55. Additional file 1 of Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers
    Elisabetta Zucchi, Valentina Bonetto, Sorarù, Gianni, Martinelli, Ilaria, Piero Parchi, Rocco Liguori, Jessica Mandrioli · 2020 · Figshare
  56. Development and pilot testing of U1 Adaptor therapy targeting SOD1 expression for dogs with degenerative myelopathy
    Natasha J. Olby, Wojciech K. Panek, Chris Galifi, Khadija Faheem, Kavita Prasad, Rafal M. Goraczniak, Marilena Perrone, Debra A. Tokarz, Samantha L. Sommer, Samuel Gunderson · 2026 · Journal of Veterinary Internal Medicine
  57. Tofersen: A Novel Option for the Treatment of Amyotrophic Lateral Sclerosis
    Michael Karros, Marissa DiFulco, Anna Nogid · 2026 · Annals of Pharmacotherapy
  58. Gene-targeted versus broad-spectrum therapies in ALS: comparative lessons and strategic outlook
    Y.Q. Shen, Siyu Shen, Zhen‐Ge Luo · 2026 · Journal of genetics and genomics/Journal of Genetics and Genomics
  59. Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
    Twinkle Chowdhury, Shanmugam Muruganandan, Daniel Ferretti, Yi Luo, Jessica Dion, Mingdi Zhang, Shih‐Ching Lo · 2026 · Journal of Visualized Experiments
  60. TIA1 Mutant Mouse Model Exhibits Motor Deficits and Neurodegenerative Characteristics of Amyotrophic Lateral Sclerosis
    Li-Hong Mao, Yuning Song, J. Zhang, Yun-ting Shao, Zhangli Wang, Na Yang, Wen-Xuan Zhang, Ying-Rui Zhang, Xiaoyan Gao, Jiayi Li et al. · 2026 · Cells
  61. Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA
    Ayşe Yeşbek Kaymaz, Gamze Bora, Hayat Erdem‐Yurter, Christopher Grunseich · 2026 · Genes
  62. Propagation et toxicité de la superoxide dismutase 1 dans la Sclérose Latérale Amyotrophique modélisée par des neurones moteurs dérivés de cellules souches pluripotentes induites
    Coline Jost-Mousseau · 2024 · theses.fr (ABES)
  63. Transcriptomic and Functional Characterization of Adeno-associated Virus Induced Dorsal Root Ganglia Toxicity in the C57BL/6J Mouse Model
    Sam Hana · 2024 · theses.fr (ABES)
  64. Genetic contributions to mitochondrial dysfunction in amyotrophic lateral sclerosis etiology
    Nikki D Russell, Jonathan M. Downie, Mark B. Bromberg, Stefan M. Pulst, Lynn B. Jorde · 2026 · Human Genetics and Genomics Advances
  65. Longitudinal CSF and Serum Biomarker Dynamics in Tofersen-Treated SOD1-ALS: A Real-World Multicentre Cohort Study
    Andrea Giordano, Jessica Mandrioli, Federica Cerri, Christian Lunetta, Hamidreza Saebfar, Marcella Catania, Claudia Battipaglia, Laura Leone, Francesca Trojsi, Maria Vizziello et al. · 2026 · International Journal of Molecular Sciences
  66. Programmable Circular Single‐Stranded DNA Acts as Recyclable Anti‐miRNA Nucleotides to Inhibit Colorectal Cancer
    Jinghao Wang, Pengfei Zhang, Guang Hu, Danlei Chen, Yonglian Huang, Kexuan Zou, Rui Ye, Xisen Cao, Qianyi Zhang, Yang Li et al. · 2026 · Small Methods
  67. Experimental Therapeutic Approaches: Molecular, Genetic, and Behavioral
    Adem Selimovic, Alyssa Soles, Marija Cvetanović · 2026 · Contemporary clinical neuroscience
  68. Pathogenic Mechanisms in Amyotrophic Lateral Sclerosis
    Aaron Held, Tiziana Petrozziello · 2026 · Springer eBooks
  69. Development and efficacy of ex vivo expanded autologous regulatory T cells for the treatment of amyotrophic lateral sclerosis
    Ya You, Huifang Zhu, Qian Zhang, Juntao Wang, Chao Dong, Zheng Yang, Jun Zhang, Yushang Zhang, Maoyan Zhang, Mingqi Lu et al. · 2026 · Frontiers in Immunology
  70. Macrophage inclusions in patients undergoing antisense oligonucleotide therapy for ALS or SMA: A retrospective and transversal study
    R. Demeret, Diane Vieles-Marais, Emmanuel Treiner, Blandine Acket, Vincent Fabry, Thierry Levade, Léonor Nogueira, J.-C. Pages, Pascal Cintas · 2026 · Revue Neurologique
  71. Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1 -ALS Autopsy Tissue Donors
    Amanda J. Guise, Monica Thanawala Sellon, Shanu Faerch Roemer, Michael I. Monine, Nicole T. Comfort, Dan Bartlett, Eric David, Shanqin Xu, Luke Jandreski, Sohail Malek et al. · 2026 · JAMA Neurology
  72. Antisense oligonucleotide treatment following viral delivery of artificial SOD1-targeting miRNA shows improved efficacy in SOD1-G93A mice
    Zachary C. E. Hawley, Amanda J. Guise, Ingrid D. R. Pardo, Twinkle Chowdhury, Sam Hana, Maria I. Zavodszky, Linda Engle, Kelly Wiltberger, Daniel Bartlett, Denitza Raitcheva et al. · 2026 · Molecular Therapy Advances
  73. UV-programmed gelatin methacryloyl hydrogel microenvironments reveal a bell-shaped vascularization window and enable compartmentalized neuromuscular disease modeling
    Chun Chuan Ni, Chun-Sheng Yu, Shih‐Yen Wei, Dai Jun-zhi, Chih-Ling Chang, Hsiao-Chien Ting, Chia-Yu Chang, Ying‐Chieh Chen · 2026 · Biomaterials
  74. Modeling Strategies for Neurodegenerative Diseases: In Vitro, In Vivo and In Silico Frameworks
    Francesca Martorella, Camilla Cigolini, Giorgia Pupo, Tiziana Alberio, Marta Lualdi · 2026 · Biomedicines
  75. Neural Stem Cell‐Derived Extracellular Vesicles Improve CNS Delivery and Therapeutic Efficacy of Antisense Oligonucleotide in Amyotrophic Lateral Sclerosis
    Yaochao Zheng, Taylor Jade Ellison, Robert Garrard, Jinghui Gao, Xinning Lai, Lin Lan, Jin Xie, Jie Jiang, Yao Yao · 2026 · Journal of Extracellular Vesicles
  76. Development of Antisense Oligonucleotide Gapmers for Amyotrophic Lateral Sclerosis
    Yuriko Nakamura, Hidenori Moriyama, Toshifumi Yokota · 2026 · Methods in molecular biology
  77. Single-Dose Intrathecal rAAV2-Retro Delivering Anti-hSOD1 miRNA Confers Robust Neuroprotection in Adult ALS Mice
    Xueqi Gong, Hao Wei, Lang Shen, Qin Wang, Jiayi Wu, Wenyuan Wang, Tonghui Xu · 2026 · Cells
  78. Beyond Monogenic Inheritance: Emerging Genetic Architecture of Amyotrophic Lateral Sclerosis
    Sherin Ramadan, Emanuele Panza, Antonio Orlacchio · 2026 · International Journal of Molecular Sciences
  79. Evaluation of Traditional Chinese and Conventional Western Pharmacotherapies for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis
    Weiquan Ren, Ran Meng, Tianyi Liang, Xudong Yang, Tianqi Wang · 2026 · Acupuncture & Electro-Therapeutics Research